Open access peer-reviewed chapter

Glycomacropeptide: Biological Activities and Uses

Written By

Juan Jauregui-Rincón, Eva Salinas-Miralles, Norma Chávez-Vela and Mariela Jiménez-Vargas

Submitted: June 19th, 2018 Reviewed: October 19th, 2018 Published: November 27th, 2018

DOI: 10.5772/intechopen.82144

Chapter metrics overview

1,221 Chapter Downloads

View Full Metrics


Glycomacropeptide (GMP) is a milk-derived bioactive peptide that comprises 15–20% of proteins present in whey, being the third most abundant. It is released from κ-casein by enzymatic digestion, either physiologically or in industry during cheese making process. GMP has many biological activities that are of particular interest for the manufacture of novel functional foods. Specifically, health promoting activities of this whey peptide are related to: antimicrobial, anticariogenic, gastric acid inhibitory, cholecystokinin releasing, prebiotic, and immune modulatory. GMP is also a peptide with promising use in food industry, due to its nutritional value and its emulsifying, foaming, and gelling properties. Besides, GMP has received much attention due to its use as an indicator of milk adulteration with cheese whey. This chapter summarizes the current knowledge about biological activities of GMP, going in-depth in immune regulatory properties, exposes the potential uses of GMP in industry, and finally reviews different methods used to detect GMP as adulteration index with cheese whey.


  • glycomacropeptide
  • bioactive peptide
  • health promoting activities
  • whey component
  • milk adulteration

1. Introduction

As already mentioned in other chapters, milk whey is a liquid by-product generated after obtaining cottage cheese or curd (proteins coagulated by acid and heat), also known as cheese whey, that for many years has been considered a waste product, and sent to bodies of water, soil, and sewage systems. However, currently it is used due to its multiple nutritional and functional properties [1].

In Mexico, the production of whey in 2016 was estimated at 1,010,000 tons, 47% of which was discharged to soil, drains, and bodies of water. Despite the fact that multiple uses have been found to cheese whey, this has become a serious environmental problem [2]. This by-product is composed of water, lactose, proteins, peptides, fat, and mineral salts [3]. One of the peptides of interest is glycomacropeptide (GMP), which is obtained after the coagulation of milk κ-casein during cheese production and represents 15–20% (w/w) of the total proteins contained in milk whey [4].

GMP is the C-terminal fragment released by the proteolytic action of the endopeptidase chymosin (renin) on κ-casein during the initial stages of cheese making, or by the action of pepsin during the gastric digestion. κ-casein is hydrolyzed at phenylalanine105-methionine106 bond, forming two very different polypeptides. One is called para-κ-casein (residues 1–105), and it is slightly cationic at pH 6.6, hydrophobic and poorly soluble, which remains in cheese curd; and the other is GMP (residues 106–169), that is strongly polar so diffuses into the aqueous phase, being eliminated during the draining with the cheese whey (as reviewed in [5]).


2. Chemical properties and molecular structure of GMP

GMP has 64 amino acid residues, with an isoelectric point (pI) between 4 and 5. Fifty percent of GMP is deglycosylated and is known as caseinomacropeptide (CMP) [5]. However, milk GMP can present different types of carbohydrates, such as: sialic acid, galactosyl, and N-acetylgalactosamine, which generate different glycosylated forms of the molecule. GMP is rich in amino acids such as proline, glutamine, serine, and threonine, but deficient in tryptophan, tyrosine, phenylalanine, and cysteine. The absence of aromatic amino acids in its primary structure causes that GMP does not present absorption at the wavelength of 280 nm. However, GMP can be detected at wavelengths between 205 and 226 nm and absorption differences between 210 and 280 nm are used for the characterization of GMP (as reviewed in [5]). The composition of GMP can be variable and depends on the source of serum and the fractionation technology used in its isolation [3] (Figure 1).

Figure 1.

Primary structure of bovine GMP variant A and B, where ● indicates its three phosphorylation sites and ▲ the most important glycosylation sites. Modified from Thomä-Worringer et al. [6].

As reviewed by Neelima [7], the three-dimensional structure of GMP cannot be evaluated due to its crystallization which is not possible, so it can only be seen from a purely theoretical approach. GMP is a peptide that does not possess defined secondary and tertiary structure. However, three-dimensional structure of GMP has been predicted by means of protein modeling and shows that a large part of the peptide has a strong negative charge, whereas there are three small domains with a positive charge at the N-terminal end. At pH 7.0, its mean value of the hydropathy is −0.322, and GMP is more hydrophilic than hydrophobic. The hydropathy value decreases when glycosylation of GMP increases, due to the greater amount of sialic acid residues.


3. Biological activities of GMP

The use of GMP is growing, since it is a bioactive peptide with unique nutritional and nutraceutical properties. Many biological activities of GMP have been reported, highlighting antimicrobial, anticariogenic, gastric acid inhibitory, cholecystokinin (CCK) releasing, prebiotic, and immune modulatory. Of particular interest is GMP’s capacity to modulate the immune response, due to its potential use in treatment or prevention of different immunopathologies.

One of the first antimicrobial effects observed in GMP was due to its ability to bind cholera toxin and Escherichia colienterotoxins. Chinese hamster ovary (CHO)-K1 cells undergo morphological changes in presence of cholera toxin and GMP at 20, 100, and 1000 μg/mL was able to suppress this morphological change by more than 70%. Treatment of GMP with proteinases lowered this activity, but removal of sialic acid abolished it [8]. Curiously, as GMP doses increased the inhibitory effect decreased. Authors demonstrated that sialic acid is mediating this inhibitory activity, so it could be inferred that GMP at high doses has less sialic acid available probably as consequence of its aggregation into polymers. Likewise, GMP has showed inhibitory activity on CHO-K1 cells morphological change induced by E. colithermolabile enterotoxins [9]. Later, the binding ability of GMP to intestinal pathogenic bacteria was evidenced, mainly to entherohemorragic E. coli(EHEC O157). This activity decreased when the peptide was desialylated and peroxidated, showing that sialic acid is essential to GMP attachment. Besides, GMP prevented in a dose-dependent manner the adhesion of EHEC O157 to Caco-2 cells and when it was conjugated with xylooligosaccharide or carboxymethyldextran, the release of IL-8 by Caco-2 was also suppressed [10]. The same inhibitory effect on pathogenic bacteria adhesion to Caco-2 cells was corroborated with 3[H] thymidine-labeled enterophatogenic E. coli(EPEC) Salmonella typhimuriumor Shigella flexneri[11]. Besides, it has been reported that GMP generates dose-dependent inhibition of enterotoxigenic E. coli(ETEC) K88 adhesion to ileal mucosa in vitro[12]. Finally, a recent report showed that GMP also prevents the attachment of several strains of EHEC and EPEC to Caco-2 and HT-29 mammalian cells [13]. In this study, it was demonstrated that GMP, beyond inhibiting bacterial adhesion, is able to maintain the structural integrity of tight junctions on Caco-2 monolayers, thus delaying the paracellular translocations of EPEC. However, it is important to clarify that authors did not measure the expression level of proteins associated with these junctions.

There are several in vivoassays that show a probable protective effect of GMP against pathogenic bacteria. GMP has been reported to neutralize in 80% the rate of incidence of diarrhea induced by cholera enterotoxins LT-1 in mice, and abolished that induced by LT-2 [9]. On the other hand, the addition of GMP into diets of piglets diminished the bacterial count in mucosal scrapping and abated the attachment of ETEC K88 to the intestine, mainly on the ileal mucosa where the receptor for E. coliis located [12]. Moreover, a diet supplemented with 1% GMP protected weaning piglets from damage caused by E. coliinfection, and prevented the reduction of growth, morphological damage, and the increase in intestinal permeability associated to infection [14].

In association with this antimicrobial effect, an anticariogenic activity to GMP has been demonstrated. Firstly, in vitroassays using different products that contain GMP as an active principle showed that it could inhibit the adhesion of bacteria inducing dental plaque and carious in oral cavity to surface plastic, such as Streptococcus mutans, S. sanguis, and Actinomyces viscosus[15]. Later assays corroborated these results, as the incorporation of GMP with or without caseinophosphopeptide to salivary films modified the adhesion capacity of S. sobrinusand S. mutansto bovine enamel discs [16]. This antimicrobial effect was linked to a remineralization activity of GMP, as demonstrated later through an experimental protocol in human that showed that GMP alone or combined with xylitol promotes more remineralization than commercial fluoride toothpaste [17]. The anticariogenic and remineralization activity of GMP have been claimed in several patents [15, 17].

Several studies have related GMP with the inhibition of gastric secretion. First ones were mostly developed using dogs by a group of Russian researchers. The first evidence that GMP inhibits gastric secretion was showed by Shlygin and co-workers [18] using gastrin to evoke it. Subsequent works demonstrated similar effect using different gastric secretion stimulants [19]. Some years later, it was proposed that this inhibitory effect was caused by a GMP fragment rather than the whole molecule [20, 21]. Later, injecting dogs with a protein fraction obtained from the gastric content of unweaned rats, it was observed an inhibition in dog gastric secretion to a food stimulus [22]. This inhibitory action was similar to that induced by GMP in dogs. GMP was also demonstrated to inhibit gastric motility after its intravenous injection in dogs [23]. All these experiments point out that at physiological conditions GMP may be playing a crucial role in the preservation of active milk proteins in newborn animal during natural breast feeding. In addition to dogs, other experimental models such as rats, pigs, and calves and also isolated organs were used to demonstrate that GMP induces gastric secretion inhibition in association with a decrease in blood of some regulatory digestive hormones, as gastrin and CCK (as reviewed in [24]). However, variations in used gastric stimuli, GMP dose, and origin, via of administration and experimental approach may be the cause of the differences in the reported intensity to this GMP activity.

Related with the effect of this bioactive peptide on digestive hormones, GMP has also been associated with appetite control. Several in situstudies with Wistar rats have suggested that glycosylated forms of GMP A variant could regulate food intake through CCK secretion, a hormone involved in satiety, as GMP stimulate its release [25, 26]. Nevertheless, in studies in human, GMP had no effect in the regulation of food intake over a short-term period [27], neither in the loss of body weight after 12 months of sustained consumption [28]. Likewise, GMP with different degree of glycosylation does not modify the concentration of CCK in human plasma [29]. As other authors have pointed out [27], these inconsistencies related to GMP’s effect on CCK release are probably due to dose changes in both animal models and human trials.

For many years, the prebiotic properties of GMP have been discussed. The first evidence that GMP might possess prebiotic activity arose with the bifidobacterial growth promoting effect of human’s colostrums and milk by in vitroassays [30]. In an attempt to discern the component of the milk responsible for this activity, an important role of N-acetyl-glucosamine (GlcNAc) and oligosaccharides with GlcNAc [31] was pointed out. Subsequent investigations were quite contradictory, until the prebiotic activity of GMP was demonstrated for the first time in 1984 [32]. This work showed that human GMP is a promoter of bifidobacterial growth, although the effect was lost when it was hydrolyzed, as well as when bovine GMP was used, showing the importance of the GMP peptide chain to function as a prebiotic. Eight years later, it was reasserted that peptide fraction was decisive for the prebiotic effects on bifidus [33]; while other researchers leaned by sialic acid as the inductor of the effect [34]. Following this line, the supplementation of milk with 2% GMP increased the in vitrogrowth of Bifidobacterium lactis[35]. Besides, the addition of 2 mg/mL of cow GMP to the growth medium, promoted the growth of Lactobacillus rhamnosusand Bifidobacterium thermophilum, and apparently glycosylation was not an essential factor to carry out this function [36]. On the other hand, using an artificial colon model to simulate colonic fermentation, GMP was shown to modulate the gut microbiota of elderly subjects by promoting the growth of several health-relevant taxa, like Coprococcusand Dorea, both related to resistance to pathobiont colonization [37]. Finally, a recent in vitroresearch has shown that GMP promotes the growth of Bifidobacterium longumssp. infantisin a dose-dependent manner and modulates its genes expression. Again, they found that the effect was lost with periodate GMP, suggesting that its activity is due to the oligosaccharides present in the molecule [38].

In the last years, several research groups have demonstrated that oral treatment with GMP modifies in vivothe microbiota in gut using different experimental approaches. First works were developed in mice, and showed that after 15 days of GMP treatment, there was a significant increase in Lactobacillusand Bifidobacteriain fecal samples, at the same time the number of Enterobacteriaceaeand coliforms decreased [39]. Feeding mice for 8 weeks with a GMP-enriched diet reduced Desulfovibriobacteria in normal and phenylketonuric mice; a bacteria that is associated with the pathogenesis of inflammatory bowel disease (IBD). Likewise, normal mice increased Firmicutes and phenylketonuric ones Bacteroidetes; specifically, the genus Allobaculum(associated with body weight loss [40]) and Bacteroidales, respectively [41]. In this case, the prebiotic property of GMP was associated with an increase in short chain fatty acid production, mainly acetate and propionate, that may has an important role in the regulation of immune response. So, although the prebiotic activity of GMP has been demonstrated, more research is needed to clarify whether the peptidic or carbohydrate fraction or both are involved in this bioactivity.

3.1 The immunomodulatory properties of GMP

GMP has been shown to modulate the immune response in a number of different ways. First, we summarize literature reports about regulatory activity of GMP on immune cells demonstrated by in vitroassays, and later, we will focus on those studies in which the regulatory effect of GMP on immune response was analyzed in animal models.

In relation to the immunomodulatory effects of GMP on immune cells, different in vitroapproaches have corroborated the inhibitory action of GMP on splenocyte proliferative response to mitogens, and have shown that both sialic acid residues and polypeptide portions of GMP are essential in this inhibitory effect. In 1992, it was showed that the GMP fraction obtained from κ-casein inhibited proliferation of mouse splenocytes induced by Salmonella typhimuriumlipopolysaccharide (LPS) [42]. Furthermore, GMP displayed an inhibitory activity on the proliferative response induced by concanavalin A (Con A) and phytohemagglutinin (PHA) [42, 43]. Initially, it was found that sialic acid was the key in this inhibitory activity, as it was lost after digestion with neuraminidase [44]. However, the inhibitory effect of GMP was increased after digestion with trypsin and pronase, which suggests that the peptidic chain is also involved in this immunomodulatory activity. In this regard, the same working group showed that the inhibitory effect on PHA-induced proliferative response is higher when the number of sialic acid residues is increased and that on LPS-induced proliferation is highest with a GMP fraction containing two sialic acid residues [45]. Both inhibitory effects decreased significantly after neuraminidase digestion. They also suggested that phosphate group at serine-149 plays a role in GMP binding to the mitogen receptor, as they observed a reduced inhibitory activity after GMP chymotrypsin digestion. Regarding to the associated mechanism to GMP inhibitory effect on splenocyte proliferation, it was showed that GMP stimulates the synthesis of a soluble inhibitory component, an interleukin (IL-1) receptor antagonist or IL-1ra [46, 47]. Moreover, GMP was able to bind to mouse CD4+ helper T cells and to suppress the expression of the IL-2 receptor on the cell membrane, inhibiting the PHA-induced proliferation of mouse splenocytes [48]. Subsequently, the inhibitory action of GMP on LPS-induced cellular proliferation was confirmed in mouse splenocytes, although they did not report any effect on PHA- or Con A-stimulated cells [49]. But later, controversy about the effect of GMP on the in vitroproliferation of spleen cells was generated, as it was reported that GMP increases the proliferation response of lymphocytes stimulated by Con A [50]. In this study, an increase in Foxp-3 and IL-10 expression was also demonstrated. Besides, authors showed an inhibition on secretion of IFN-γ and TNF-α and on STAT4 activation when cells were stimulated by Con A in presence of GMP. The same team studied the action of GMP on monocyte cell line THP-1 and they found that GMP increases the secretion of TNF, IL-1β, and IL-8 by THP-1 cells, and this effect is mediated via MAP kinase and NF-kB pathways [51].

On the other hand, GMP is also able to downregulate dendritic cell response to LPS by inducing a slight but significant decrease in the production of IL-6, IL-1β, and TNF-α, but without changing the production of IL-12 and IL-10 [49]. Strikingly, the regulatory effect of GMP on neutrophils is the opposite, as it improves proliferation and phagocytic activity of the human macrophage like cells U937 [52]. However, the observation that both polypeptide and carbohydrate portions are essential for GMP biological effects is reinforced in this study, as peptides of pepsin-digested GMP and sialic acid-rich GMP fractions significantly enhanced cell proliferation and phagocytic activities stimulated by non-digested or asialo-GMP on U937 cell. Also, an upregulatory effect of GMP on production of IgA by LPS-stimulated splenocytes has been reported, being correlated with an increase in the population of IgA positive cells [53].

There are several studies that analyze the immunomodulatory activity of GMP on immune response when it is orally administered to experimental animals. In the context of splenocytes response to mitogens, two in vivostudies were carried out to analyze the possible immunomodulatory activity of GMP. First one was developed in 1998 and demonstrated that mice fed with a GMP-supplemented diet show an enhanced proliferative response of spleen cells to Con A, without generating significant changes in the response to LPS or PHA [54]. Later in 2012, it was showed that oral intake of GMP by rats reduces the proliferative response of splenocytes induced by Con A [55]. In both in vivostudies, animals were antigen-immunized because antibody response was also measured. All together in vitroplus in vivostudies, point out the inhibitory effect of GMP on splenocyte proliferation to mitogens. The opposite response reported by one in vitro[50] and in vivo[54] assay was quite possibly due to concentration-dependent effects or assay-used conditions.

The effect of orally administered GMP on humoral immunity has also been studied. Mice fed with GMP have shown suppressed levels of specific IgG to dietary and injected antigens, with no change in IgM, IgA, and IgE antibody response [54]. In this regard, a recent study showed that oral administration of GMP to mice resulted in a greater number of IgA positive plasma cells in the intestinal lamina propria [56]. All these results [54, 56] plus in vitroones [53] about Igs production fit together, suggesting an immuno-suppressing activity of GMP on systemic humoral response, but an immuno-stimulating activity on humoral mucosal immunity.

Martínez-Augustin and co-workers [57, 58] have studied the immunomodulatory action of GMP in experimental models of intestinal inflammation. They have demonstrated that GMP administered orally to rats exerts an anti-inflammatory effect in ileitis and colitis induced with trinitrobenzenesulfonic acid (TNBS); said anti-inflammatory effect shows a degree of efficacy similar to that of sulfasalazine, a drug widely used in the treatment of inflammatory bowel disease. GMP was shown to protect rats from TNBS-induced colonic and ileal inflammatory damage, by reducing the damage score and the extent of necrosis, and also by diminishing the increased alkaline phosphatase colonic activity and inducible oxide nitric synthase expression. IL-1β and IL-1ra messenger RNA levels were significantly decreased in colon as a consequence of GMP administration; and myeloperoxidase activity and levels of IL-1β and IL-17 were decreased in ileum. Initially, the authors assumed that the action mechanism of GMP was not related to anti-oxidative activity or to regulatory cell induction, as glutathione or TGF-β levels in colon and Foxp-3 in ileum were not affected [57, 58]. However, when GMP was orally administered to rats, an increase on Foxp3 expression in spleen cells was observed, although secretion of cytokines by ex vivoCon A-stimulated splenocytes did not change [50]. Putting together these results with the regulatory activity of GMP on monocytes (THP-1) and splenocytes cytokine response obtained by the same working group and previously mentioned in this review [50, 51], authors concluded that the intestinal anti-inflammatory action of GMP is likely to be mediated by the direct modulation of monocyte or splenocyte activity, especially by hampering the activation of Th1 cells while favoring the differentiation of Treg cells [50].

In recent years, a Mexican laboratory led by Salinas [55, 59, 60, 61] has focused on the study of the immunomodulatory activity of GMP in experimental allergy models. They found that oral administration of GMP to rats before and during sensitization with allergen significantly reduces the level of allergen-specific IgE in serum, and also decreases the proliferative response and the production of IL-13 by splenocytes stimulated by the allergen [55]. Treatment of animals with GMP also protected them from systemic anaphylaxis as GMP administration increased survival rates and lessened signs of severity of anaphylactic shock. Moreover, GMP reduced the intensity of urticarial inflammatory reaction when sensitized animals were intradermically challenged with the allergen [55]. With these results, it was demonstrated the immunomodulatory properties of GMP on allergic sensitization and its beneficial effect on clinical signs associated to early-phase allergic reaction. Then, they investigated whether GMP may impact on late-phase and chronic inflammatory allergic reactions, using two experimental models that after repetitive exposure to allergens displayed local recruitment and activation of immune cells with persistent production of inflammatory mediators in affected tissues, together with substantial changes in the extracellular matrix and alterations in structural cells [62]. Specifically, they used experimental models of asthma and atopic dermatitis prophylactically administered with GMP, that is to say, prior to and during pathology establishment. As expected, GMP intake resulted in reduction of IgE titers in serum. In addition to this, in asthma model, GMP substantially decreased blood eosinophilia and suppressed the recruitment of inflammatory cells to the bronchoalveolar compartment. GMP also inhibited eosinophils infiltration, goblet cells hyperplasia, and collagen deposit in lung tissue [59]. Equivalent results were obtained in allergen-induced atopic dermatitis model, where GMP reduced the intensity of cutaneous inflammatory process and edema, abolished pruritus, and reduced eosinophils recruitment and mast cells hyperplasia in dermis [60]. In both models, expression of IL-5 and IL-13 was markedly inhibited in lung and skin, while expression of IL-10 was increased. Their research then turned to the mechanism by which GMP modulates the allergic response. They demonstrated that GMP administration increases the amount of Lactobacillusand Bifidobacteriumpresent in gut of allergen-sensitized animals after 3 days of oral treatment, and that of Bacteroidesafter 17 days. Interestingly, this intestinal microbiota is associated with protection in allergy. GMP intake also increased the production of TGF-β by splenocytes of sensitized animals in response to allergen and impacted mast cell function, inhibiting their activation and also the release of histamine in response to allergens. No change in tissue mast cell number was found [61]. These results obtained in experimental allergy models again show a double way by means GMP exerts its control on inflammation; on one hand, through a direct modulation of immune cells activity involved in the process, and on other side by potentiating a regulatory microenvironment against the Th2-inflammatory one. More studies are needed to understand which immune cell receptors recognize GMP and which intracellular signals activate or inhibit.

Finally, there are few studies that analyze the role of GMP on cancer. In a rat model of pharmacological-induced colorectal cancer, oral administration of 100 mg/kg of GMP decreased the number of aberrant crypt foci although no effect was observed at doses of 10 and 50 mg/kg. On the other hand, there was no change in methylation and expression level of p16 and MUC2, two tumor suppressor genes [63]. Additionally, through an in vitroassay GMP was showed to inhibit the expression of p65 NF-kB in human colorectal tumor HT-29 cells activated with LPS, key element in colorectal cancer induced by inflammatory bowel diseases [64].

Although more studies are needed in relation to some biological activities, current results propose GMP as a good candidate to be used as a functional ingredient in food industry.


4. Potential uses of GMP

Today, one of the objectives of the food industry is the development of novel food products with beneficial properties for health. For its different health benefits, GMP can be used in therapeutic and dietary foods, or as a functional ingredient in various special products, like oral care products.

4.1 Therapeutic and nutritional applications

It is crucial to demonstrate that GMP is hypoallergenic to be used in food compositions. In this regard, Takahashi and collaborators patented a food composition that contained GMP and a mixture of free amino acids (leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, tryptophan, arginine, histidine, and glycine) [65]. The composition presented good taste, good absorption and digestion properties, and a high nutritional value. They demonstrated that this composition was hypoallergenic, as after repeated injections of the GMP composition together with an adjuvant used to induce experimental allergy in mice, no antibody against GMP was detected in serum by Ouchterlony. Although this method is not very accurate, GMP hypoallergenicity was later corroborated by Milkkelsen and collaborators using ELISA test to show absence of specific antibodies in mice after being sensitized both systemically or orally with GMP [66].

Due to the particular amino acid composition of GMP, devoid of aromatics amino acids (phenylalanine, tryptophan, and tyrosine), it can be used for special diets of people suffering from phenylketonuria (PKU), being an adequate choice as a source of proteins [67]. On the other hand, GMP has low amount of methionine but high amount of branched chain amino acids (valine and isoleucine), which makes this peptide an excellent candidate to be used for the control of liver diseases, as this type of amino acids are good as caloric sources [68]. There is a patent to use of GMP to improve female’s health [69]. The inventors claim that administration of a composition comprising GMP can improve the health of the females. They used murine models fed with GMP composition and showed that females decreased final fat mass and percent body fat, when comparing with females that received a diet based on caseins or free amino acids as source of proteins. In relation to bone characteristics, femur length was larger in GMP administered mice, although only females showed less femoral weakness and greater bone mineral content and density as compared to those fed with amino acids or casein diets, respectively.

4.2 Dietary supplementation

As previously mentioned, research results suggest that GMP has an effect on the feeling of fullness but this does not translate into a lower food intake [27, 28]. For an application in food intake regulation and in potentially body weight management, more work is required. Understanding dose, timing, and delivery mode, including food form and composition, in relation to the pattern of release of CCK, is needed for the use of GMP as appetite suppressant [70].

4.3 Food additive

GMP has physicochemical properties that make it attractive for use as an additive in food products. According to studies on the functional properties of GMP, it can act as an emulsifier, foaming, and gelling agent.

GMP as an emulsifier presents stability to pH variations, which is attractive for foods that undergo pH changes during their process, such as the case of fermented milk products [71]. The best emulsifying capacity was obtained at alkaline pH. However, it has been observed that emulsions with GMP as emulsifying agent are not stable during storage when they have received thermal treatment [72]. Besides, GMP modified covalently with disaccharides or fatty acids can present an improved function and even increase its biological activity [73, 74]. Therefore, in order to modify the emulsification activity of GMP, this peptide has been conjugated with other molecules such as lactose [73] and fatty acids [74]. The conjugation of GMP with lactose was carried out through the reaction of Maillard, and this conjugate showed a better emulsifying capacity without significantly reducing the solubility of GMP [73].

Currently, foams have many industrial uses of great importance in the production of beer, soaps, whipped cream, shaving cream, aerosols, etc. The formation of a foam requires the participation of a surfactant capable of diffusing to the air/water interface to lower the surface tension. GMP complies with this property, although the foams formed with GMP are stronger or more stable when combined with other foaming proteins [75, 76]. In order to improve the foam properties of the proteins, synergistic mixtures of biopolymers and pH variations have been made that can modify their charge and, consequently, their foam ability. In relation to this, by combining sodium caseinate with GMP, synergistic interactions take place between these molecules on foaming and on stability at pH 5.5 [77]. Non-glycosylated GMP has better foaming properties than glycosylated GMP [78]. This is due to the glycosidic structures favor a combination of hydrophilic and electrostatic effects, which prevents an orderly adsorption of the glycosylated GMP molecules at the air/water interface; whereas, non-glycosylated GMP forms a very stable network at the interface.

On the other hand, gels are semi-solid systems that consist of a network of solids (three-dimensional network of polymers) with an inside trapped-liquid. They are of great importance in food and pharmaceutical industry as many gelled products are manufactured throughout the world (gummies, gelatins, jelly jams, bakery fillings, and therapeutic or cleaning agents). Generally, gelling agents are proteins and polysaccharides. Gelling properties of GMP has been studied and it is known that its gelation depends on pH and temperature, reporting that even aqueous solutions with low GMP amounts can be gelled at pH below 4 [79]. Besides, GMP can potentiate gellying capacity of other substances. Thus, by fermenting goat milk to which GMP was added, a more ordered and structured gel was obtained, in addition to obtaining a better elasticity in it, as compared to that obtained when whey protein concentrate was added [80]. The influence of GMP on the gelation made by gelatin has also been studied and when these two compounds are mixed, lower concentration of both substances are need to get a gel as compared with the ones need when they are used separately [81]. This synergistic effect in gelation is very important in the food industry for the preparation of desserts and foods based on gels.

4.4 Oral care products

Dental caries is one of the chronic diseases that most often affect humans. Due to the anticariogenic and remineralization properties demonstrated to GMP and previously reviewed in biological activities section, nowadays GMP is being incorporated to some oral care products [15, 16, 17].


5. GMP as an indicator of milk adulteration with cheese whey

One of the problems presented by the dairy industry is the adulteration of milk with whey cheese, which is very cheap and not detected by sensorial tests. Cheese whey does not cause harm to health, however, it affects milk-derived products manufacturers financially and can affect the consumers nutritionally, so the addition of cheese whey is considered a fraud. Due to GMP present in cheese whey, the detection of this peptide may indicate the addition of cheese whey to milk. Some of the methods that detect GMP as an indicator of the presence of cheese whey are described below.

5.1 Electrophoretic methods

Sodium dodecyl sulfate−polyacrylamide gel(SDS-PAGE): This method was standardized to analyze pasteurized milk and milk powder. Samples has to be previously treated with 24% trichloroacetic acid (TCA) to eliminate interfering k-casein and later with 50% TCA to precipitate GMP, which is resuspended in Tris-buffer 0.05 M HCl, 1 mM EDTA, pH 7.2 [82]. Analyzing under these conditions cheese whey and milk added with cheese whey, a protein fraction of 20.8 kDa is identified corresponding to GMP that allowed to detect adulteration with whey up to 1%. This protein fraction is not detected in samples of acid whey or in raw milk. This technique had been previously used to analyze milk drinks that were distributed in schools as part of a program of the Brazilian government [83]. However, the method showed sensitivity to detect 5% of added whey, probably because they did not treat the sample with TCA. In later works, it was able to detect 40 and 20 μg of GMP in samples analyzed by electrophoresis in SDS-PAGE and in cellulose acetate strips, respectively, due to the use of thiobarbituric acid and malachite green dye reactions instead of Coomassie blue as developing agents [84].

Capillary electrophoresis(CE): A variant of electrophoresis is CE, a technique that has the advantage of allowing a rapid detection of GMP. This method has been used to identify GMP as an indicator of the presence of cheese whey in buttermilk powder and skim milk. An advantage of this method is that it is usually reproducible, repeatable and sensitive; however, the interpretation of the results is difficult [85].

5.2 Chromatographic method

High performance liquid chromatography (HPLC) has been widely used to identify GMP as indicative of milk adulteration with cheese whey. In order to carry out the analysis, it is necessary to pre-treat the samples with TCA to precipitate proteins that can interfere (k-casein) and to concentrate GMP [86]. Similarly, a rapid and sensitive HPLC method on a gel permeation column was developed to detect GMP to follow the hydrolysis of k-casein by chymosin in milk [87]. The only pretreatment given to samples was addition of TCA (final concentration 8%) to precipitate the interfering caseins and whey proteins. This method was widely used by several researchers to analyze different samples, such as skimmed milk powder [88]. Cation-exchange chromatography has also been used to detect GMP, previously removing caseins from whey samples by precipitation with HCl at pH 4.6, neutralizing with TCA at 2–8% and analyzing supernatants [89]. On the other hand, a Reversed-Phase HPLC (RP-HPLC) method was developed and validated to separate and quantify GMP and was demonstrated to be precise, sensitive, and reliable [90]. The determinations were performed in the linear range of 15–200 μg/mL and the detection limit was 2 μg/mL. The method was applied to the analysis of rennet and acid whey, whey protein concentrates produced by the dairy industry, and also for the detection of rennet whey in powdered milks.

The European Commission uses two methods to detect the presence of cheese whey in milk: a gel permeation chromatography and subsequently a RP-HPLC as a confirmatory test [91]. However, it has been shown that the sensitivity of this method is affected by the presence of acidified rennet whey, which makes it difficult to detect the addition of whey [92]. Besides, the HPLC methodology used to analyze compounds like GMP in dairy products usually includes extractions with solvents, sample’s preparation require a lot of time and reactives, the equipment is very sophisticated and demands trained personal.

5.3 Spectroscopy methods

Spectroscopy has also been used to detect GMP. The medium infrared spectroscopy (MIR) was used to analyze milk powder in order to detect GMP as adulteration parameter. Although this method is fast, it is not widely used because derived spectra are not very easy to interpret, in addition to its high cost [93]. On the other hand, by liquid chromatography/electrospray coupled to mass spectrometry, milk products were analyzed and it was able to quantify GMP from concentration of 10 pmol, although the method was not used to detect milk adulteration [94].

5.4 Immunochemical methods

Immunoassays are analytical methods of great application in the food area, and have the advantages that they are quick, sensitive, and that the sample to be analyzed requires little or no treatment. Several immunochemical methods have been developed in order to identify and quantify GMP in milk. Firstly, it is necessary to produce antibodies against GMP and later, these antibodies can be used for the development of the different immunochemical methods that detect it. Some of these assays are described below:

Enzyme-linked immunosorbent assay(ELISA): It is an immunoassay widely used to analyze foods. It has the advantage that is simple, sensitive, and fast, in addition to being inexpensive. Two main ELISA assays has been developed to detect GMP in milk samples. An inhibition ELISA method was performed to detect bovine rennet whey solids in skim milk powders that presented a detection limit of 0.1% (w/w) and used enzyme-labeled monoclonal antibodies against bovine k-casein [95]. On the other hand, Chávez and co-workers [96] developed a sandwich ELISA using polyclonal antibodies against GMP, that showed a limit of detection of 0.047% (w/w).

Western blot assay: As ELISA, this technique is an immunoassay designed to detect proteins in complex samples and also has great specificity. Using the same polyclonal antibodies against GMP previously mentioned, Chávez and co-workers developed a western blot system to detect GMP [97]. When analyzing cheese whey, this antibody recognized three protein fractions of 20.1, 14, and 45 kDa. The detection limit of the test was 0.5% (v/v) to liquid cheese whey and 0.001% (w/w) to whey powder.

Immunochromatographic lateral-flow assay: The development of immunochromatographic systems for quality control is a relatively new field of research and has been applied to milk. There are commercial immunochromatographic sticks which contain monoclonal antibodies specific to GMP labeled with colloidal particles that present a limit detection of 4% (v/v) of milk whey. Using these immunosticks, it has been possible to identify GMP in different samples of commercial milks [98]. Besides, it has been developed an immunochromatographic lateral-flow test that used two specific anti-bovine κ-casein monoclonal antibodies, with a detection limit of 15 ng/ml of GMP and 1% (v/v) of cheese whey [99].

In summary, different techniques and methods have been developed and used to detect GMP as an index of adulteration of milk with cheese whey. Some of them can also be used to quantify GMP in food products. The aim of this area of research is to achieve one that bring together being cheap, fast, easy to develop, and to interpret the results, with high sensitivity and a limited sample processing. These characteristics will allow people to use them at the time and place of milk reception.


6. Conclusions

GMP possesses several nutritional and health promoting properties. Among them, it exerts important modulatory effects on the immune system that are beneficial in a number of different inflammatory conditions. GMP immune response mechanism of action might be mediated by increasing healthy intestinal microbiota, by inhibiting splenocyte proliferation, by promoting both local and systemic regulatory environment, and also by directly modulating immune cell functions. More research is needed to support these findings, as we cannot exclude a possible effect of products derived from GMP digestion on in vivoimmunomodulatory activity. Besides, GMP is a peptide of promising industrial potential. It has a unique heat stability and solubility under acidic conditions that may suggest several uses in food. Studies on the functional properties of GMP may indicate new possible uses as a food additive. On the other hand, several methods have been developed and applied to detect GMP as an indicator of milk adulteration with cheese whey; however, none of them has been established as an international official method. Rapid, reliable, and inexpensive tests to detect GMP should be worked out to readily detect those cases of adulteration.



We appreciate the support given to the Autonomous University of Aguascalientes for the publication of this chapter.


Conflict of interest

Authors declare that there is no conflict of interest between the authors of the chapter entitled: “Glycomacropeptide: Biological activities and uses.”


  1. 1. Hernández-Rojas M, Vélez-Ruiz JF. Suero de leche y su aplicación en la elaboración de alimentos funcionales. Temas Selectos de Ingeniería de Alimentos. 2014;8(2):13-22
  2. 2. Universidad Tecnológica del Valle del Mezquital. Citrato de calcio a partir de residuos agroindustriales [Internet]. 2017. Available from:[Accessed: 30-05-2018]
  3. 3. Nishanthi M, Chandrapala J, Vasiljevic T. Compositional and structural properties of whey proteins of sweet, acid and salty whey concentrates and their respective spray dried powders. International Dairy Journal. 2017;74:49-56. DOI: 10.1016/j.idairyj.2017.01.002
  4. 4. Moreno FJ, López-Fandiño R. Estructura y funcionalidad del glicomacropéptido bovino. In: Fontecha J, Recio I, editors. Funcionalidad de Componentes Lácteos. Elche: Universidad Miguel Hernández; 2009. pp. 223-249
  5. 5. Tomczak-Tullio L, Lazzari-Karkle EN, Bileski-Cândido LM. Review: Isolation and Purification of Milk Whey Glycomacropeptide. Boletim do Centro de Pesquisa de Processamento de Alimentos in Curitiba. 2007;25(1):121-132
  6. 6. Thomä-Worringer C, Sørensen J, López-Fandiño R. Review: Health effects and technological features of caseinomacropeptide. International Dairy Journal. 2006;16:1324-1333. DOI: 10.1016/j.idairyj.2006.06.012
  7. 7. Neelima SR, Singh Rajput Y, Man B. Chemical and functional properties of glycomacropeptide (GMP) and its role in the detection of cheese whey adulteration in milk: A review. Dairy Science and Technology. 2013;93:21-43. DOI: 10.1007/s13594-012-0095-0
  8. 8. Kawasaki Y, Isoda H, Tanioto M, Dosako S, Idota T, Ahiko K. Inhibition by lactoferrin and κ-casein glycomacropetide of binding of cholera toxin to its receptor. Bioscience, Biotechnology, and Biochemistry. 1992;56(2):195-198. DOI: 10.1371/journal.pone.0059253
  9. 9. Isoda H, Kawasaki Y, Tanimoto M, Dosako S, Idota T. Patent: Use of compounds containing or binding sialic acid to neutralize bacterial toxins. European patent. Publication date: Sep 5, 1990; publication number: 0 385 118 A2
  10. 10. Nakajima K, Tamura N, Kobayashi-Hattori K, Yoshida T, Hara-Kudo Y, Ikedo M, et al. Prevention of intestinal infection by glycomacropeptide. Bioscience, Biotechnology, and Biochemistry. 2005;69(12):2294-2301
  11. 11. Brück WM, Kelleher SL, Gibson GR, Graverholt G, Lönnerdal BL. The efects of a-lactalbumin and glycomacropeptide on the association of CaCo-2 cells by enteropathogenicEscherichia coli,Salmonella typhimuriumandShigella flexneri. FEMS Microbiology Letters. 2006;259:158-162. DOI: 10.1111/j.1574-6968.2006.00268.x
  12. 12. Hermes RG, Molist F, Pérez JF, Gómez de Segura A, Ywasaki M, Davin R, et al. Casein glycomacropeptide in the diet may reduceEscherichia coliattachment to the intestinal mucosa and increase the intestinal lactobacilli of early weaned piglets after an enterotoxigenicE. coliK88 challenge. The British Journal of Nutrition. 2013;109(6):1001-1012. DOI: 10.1017/S0007114512002978
  13. 13. Feeney S, Tyan JT, Kilcoyne M, Joshi L, Hickey R. Glycomacropeptide reduces intestinal epithelial cell barrier dysfunction and adhesion of entero-hemorrhagic and entero-pathogenicEscherichia coliin vitro. Food. 2017;6:93. DOI: 10.3390/foods6110093
  14. 14. Rong Y, Lu Z, Zhang H, Zhan L, Song D, Wang Y. Effects of casein glycomacropeptide supplementation on growth performance, intestinal morphology, intestinal barrier permeability and inflammatory responses inEscherichia coliK88 challenged piglets. Animal Nutrition. 2015;1(2):54-59. DOI: 10.1016/j.aninu.2015.05.006
  15. 15. Nesser JR. Patent: Dental anti-plaque and anti-caries agent. Publication date: Feb 19, 1991; publication number: 4, 994, 441
  16. 16. Schüpbach P, Neeser JR, Golliard M, Rouvet M, Guggenheim B. Incorporation of caseinoglycomacropeptide and caseinophosphopeptide into the salivary pellicle inhibits adherence of mutans streptococci. Journal of Dental Research. 1996;75(10):1779-1788. DOI: 10.5167/uzh-1649
  17. 17. Zhang YP, Gaffar A. Patent: Fluoride free dental remineralization. Publication date: Mar 27, 2001; publication number: US 6,207,138 B1
  18. 18. Shlygin GK, Vasilevskaya LS, Chernikov MP, Nikol’skaya GV. Antigastrin action of glycomaropeptide. Byulleten Eksperimental'noi Biologii i Meditsiny. 1971;72(12):9-13
  19. 19. Vasilevskaia LS, Stan EI, Chernikov MP, Shlygin GK. Inhibiting action of glycomacropeptide on stomach secretion induced by various humoral stimulants. Voprosy Pitaniia. 1977;4:21-24
  20. 20. Stan EI, Chernikov MP. Physiological activity of kappa-casein glycomacropeptide. Voprosy medit︠s︡inskoĭ khimii. 1979;25(3):348-352
  21. 21. Chernikov MP, Stan EI, Vasilevskaia LS, Shlygin GK. Heterogeneity of the kappa-casein glycomacropeptide and physiological activity of its fractions. Voprosy Pitaniia. 1979;5:22-26
  22. 22. Stan EY, Chernikoz EY. Formation of a peptide inhibitor of gastric secretion from rat milk proteins in vivo. Biulleten' Eksperimental'noĭ Biologii i Meditsiny. 1982;94(2):1087-1089
  23. 23. Stan EI, Groĭsman SD, Krasil'shchikov KB, Chernikov MP. Effect of kappa-casein glycomacropeptide on gastrointestinal motility in dogs. Biulleten' Eksperimental'noĭ Biologii i Meditsiny. 1983;96(7):10-12
  24. 24. Yvon M, Beucher S, Guilloteau P, Le Huerou-Luron I, Corring T. Effects of caseinomacropeptide (CMP) on digestion regulation. Reproduction, Nutrition, Development. 1994;34(6):527-537
  25. 25. Beucher S, Levenez F, Yvon M, Corring T. Effects of gastric digestive products from casein on CCK release by intestinal cells in rat. The Journal of Nutritional Biochemistry. 1994;5(12):578-584. DOI: 10.1016/0955-2863(94)90012-4
  26. 26. Pedersen NL, Nagain-Domaine C, Mahé S, Chariot J, Rozé C, Tomé D. Caseinomacropeptide specifically stimulates exocrine pancreatic secretion in the anesthetized rat. Peptides. 2000;21(10):1527-1535
  27. 27. Gustafson DR, McMahon DJ, Morey J, Nan R. Appetite is not influenced by a unique milk peptide: Caseinomacropeptide (CMP). Appetite. 2001;36:157-163
  28. 28. Keogh JB, Clifton P. The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. The American Journal of Clinical Nutrition. 2008;87:1602-1605. DOI: 10.1093/ajcn/87.6.1602
  29. 29. Keogh JB, Wooton BW, Taylor CM, Janakievski F, Desilva K, Clifton PM. Effect of glycomacropeptide fractions on cholecystokinin and food intake. British Journal of Nutrition. 2010;104:286-290. DOI: 10.1017/S0007114510000280
  30. 30. György P, Kuhn R, Rose CS, Zilliken F. Bifidus factor. II. Its occurrence in milk from different species and in other natural products. Archives of Biochemistry and Biophysics. 1954;48(1):202-208. DOI: 10.1016/0003-9861(54)90324-0
  31. 31. György P, Jeanloz RW, Nicolai H, Zilliken F. Undializable growth factors forLactobacillus bifidusvar. Pennsylvanicus. European Journal of Biochemistry. 1974;43:29-33. DOI: 10.1111/j.1432-1033.1974.tb03380.x
  32. 32. Azuma N, Yamauchi K, Mitsuoka T. Bifidus growth-promoting activity of a glycmcropeptide derived from human K-casein. Agricultural and Biological Chemistry. 1984;48(8):2159-2162. DOI: 10.1080/00021369.1984.10866469
  33. 33. Proulx M, Gauthier SF, Roy D. Effect of casein hydrolysates on the growth of bifidobacteria. Le Lait. 1992;72:393-404. DOI: 10.1051/lait:1992428
  34. 34. Idota T, Kawakami H, Nakajima I. Growth-promoting effects of N-actylneuraminic acid-containing substances on bifidobacteria. Bioscience, Biotechnology, and Biochemistry. 1994;58:1720-1722. DOI: 10.1271/bbb.58.1720
  35. 35. Janer C, Peláez C, Requena T. Caseinomacropeptide and whey protein concentrate enhanceBifidobacterium lactisgrowth in milk. Food Chemistry. 2004;86(2):263-267. DOI: 10.1016/j.foodchem.2003.09.034
  36. 36. Robitaille G. Growth-promoting effects of caseinomacropeptide from cow and goat milk on probiotics. Journal of Dairy Research. 2013;80:58-63. DOI: 10.1017/S0022029912000660
  37. 37. Ntemeri A, Chonchúir FN, O’Callagan TF, Stanton C, Ross RP, O’Toole PW. Glycomacropeptide sustains microbiota diversity and promotes specific taxa in an artificial colon model of elderly gut microbiota. Journal of Agricultural and Food Chemistry. 2017;65:1836-1846. DOI: 10.1021/acs.jafc.6b05434
  38. 38. O’Riordan N, O’Callagan J, Buttò LF, Kilcoyne M, Joshi L, Hickey RM. Bovine glycomacropeptide promotes the growth ofBifidobacterium longumssp. infntis anda modulates its gene expression. Journal of Dairy Science. 2018;101:1-12. DOI: 10.3168/jds.2018-14499
  39. 39. Chen Q, Cao J, Jia Y, Liu X, Yan Y, Pang G. Modulation of mice fecal microbiota by administration of casein glycomacropeptide. Microbiology Research. 2012;3(1):e3. DOI: 10.4081/mr.2012.e3
  40. 40. Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity. 2012;20(4):738-747. DOI: 10.1038/oby.2011.111
  41. 41. Sawin EA, De Wolfe TJ, Aktas B, Stroup BM, Murali SG, Steele JL, et al. Glycomacropeptide is a prebiotic that reducesDesulfovibriobacteria, increases cecal short-chain fatty acids, and is anti-inflmatory in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2015;309:G590-G601. DOI: 10.1152/ajpgi.00211.2015
  42. 42. Otani H, Monnai M, Hosono A. Bovine k-casein as inhibitor of the proliferation of mouse splenocytes induced by lipopolysaccharide stimulation. ZB MED Nutrition, Environment, Agriculture. 1992;47:512-515
  43. 43. Otani H, Hata I. Inhibition of proliferative responses of mouse spleen lymphocytes and rabbit Peyer's patch cells by bovine milk caseins and their digests. Journal of Dairy Research. 1995;62:339-348. DOI: 10.1080/09540109309354801
  44. 44. Otani H, Monnai M. Inhibition of proliferative responses of mouse spleen lymphocytes by bovine milk k-casein digests. Food and Agricultural Immunology. 1993;5:219-229. DOI: 10.1080/09540109309354801
  45. 45. Otani H, Monnai M, Kawasaki Y, Kawakami H, Tanimoto M. Inhibition of mitogen-induced proliferative responses of lymphocytes by bovine k-caseinoglycopeptides having different carbohydrate chains. Journal of Dairy Research. 1995;62:349-357. DOI: 10.1017/S0022029900031046
  46. 46. Otani H, Monnai M. Induction of an interleuken-1 receptor antagonist-like component produced from mouse speen cells by bovine k-caseinoglycopeptide. Bioscience, Biotechnology, and Biochemistry. 1995;59:1166-1168. DOI: 10.1271/bbb.60.1017
  47. 47. Monnai M, Otani H. Effect of bovine k-caseinoglycopeptide on secretion of interleukin-1 family cytokines by P388D1 cells, a line derived from mouse monocyte/macrophage. Milchwissenschaft. 1997;52:192-196
  48. 48. Otani H, Horimoto Y, Monnai M. Suppression of interleukin-2 receptor expression on mouse CD4 + T Cells by bovine k-caseinoglycopeptide. Bioscience, Biotechnology, and Biochemistry. 1996;60:1017-1019. DOI: 10.1271/bbb.60.1017
  49. 49. Mikkelsen TL, Bakman S, Sørensen ES, Barkholt V, Frøkiaer H. Sialic acid-containing milk proteins show differential immunomodulatory activities independent of sialic acid. Journal of Agricultural and Food Chemistry. 2005;53(20):7673-7680. DOI: 10.1021/jf050398o
  50. 50. Requena P, González R, López-Posadas R, Abadía-Molina A, Suárez MD, Zarzuelo A, et al. The intestinal antiinflammatory agent glycomacropeptide has immunomodulatory actions on rat splenocytes. Biochemical Pharmacology. 2010;79(12):1797-1804. DOI: 10.1016/j.bcp.2010.02.008
  51. 51. Requena P, Daddaoua A, Guadix E, Zarzuelo A, Suárez MD, Sánchez de Medina F, et al. Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-kappaB signal transduction pathways. British Journal of Pharmacology. 2009;157(7):1232-1240. DOI: 10.1111/j.1476-5381.2009.00195.x
  52. 52. Li EW, Mine Y. Immunoenhancing effects of bovine glycomacropeptide and its derivatives on the proliferative response and phagocytic activities of human macrophagelike cells, U937. Journal of Agricultural and Food Chemistry. 2004;52(9):2704-2708. DOI: 10.1021/jf0355102
  53. 53. Yun SS, Sugita-Konishi Y, Kumagai S, Yamauchi K. Glycomacropeptide from cheese whey protein concentrate enhances IgA production by lipopolysaccharide-stimulated spleen cells. Animal Science Technology (Japan). 1996;67:458-462. DOI: 10.2508/chikusan.67.458
  54. 54. Monnai M, Horimoto Y, Otani H. Immunomodificatory effect of dietary bovine k-caseinoglycopeptide on serum antibody levels and proliferative responses of lymphocytes in mice. Milchwissenschaft. 1998;53(3):131-139
  55. 55. Jiménez M, Chávez NA, Salinas E. Pretreatment with glycomacropeptide reduces allergen sensitization, alleviates immediate cutaneous hypersensitivity and protects from anaphylaxis. Clinical and Experimental Immunology. 2012;170(1):18-27. DOI: 10.1111/j.1365-2249.2012.04631.x
  56. 56. Ye L, Chen Q, Li W, Yan Y, Zhao P, Pang G, et al. Effect of casein glycomacropeptide on phagocytic cells and intestinal mucosa immune cells in mice. Food Science. 2014;35(9):234-240. DOI: 10.1021/acs.jafc.5b04757
  57. 57. Daddaoua A, Puerta V, Zarzuelo A, Suárez MD, Sánchez de Medina F, Martínez-Augustin O. Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis. Journal of Nutrition. 2005;135(5):1164-1170. DOI: 10.1093/jn/135.5.1164
  58. 58. Requena P, Daddaoua A, Martínez-Plata E, González M, Zarzuelo A, Suárez MD, et al. Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. British Journal of Pharmacology. 2008;154(4):825-832. DOI: 10.1038/bjp.2008.138
  59. 59. Roldán NR, Jiménez M, Cervantes-García D, Marín E, Salinas E. Glycomacropeptide administration attenuates airway inflammation and remodeling associated to allergic asthma in rat. Inflammation Research. 2016;65(4):273-283. DOI: 10.1007/s00011-015-0913-y
  60. 60. Muñoz FC, Cervantes MM, Cervantes-García D, Jiménez M, Ventura-Juárez J, Salinas E. Glycomacropeptide attenuates inflammation, pruritus, and Th2 response associated with atopic dermatitis induced by 2,4-dinitrochlorobenzene in rat. Journal of Immunological Research. 2017;2017:6935402. DOI: 10.1155/2017/6935402
  61. 61. Jiménez M, Cervantes-García D, Muñoz YH, García A, Haro LM Jr, Salinas E. Novel mechanisms underlying the therapeutic effect of glycomacropeptide on allergy: Change in gut microbiota, upregulation of TGF-β, and inhibition of mast cells. International Archives of Allergy and Immunology. 2016;171(3-4):217-226. DOI: 10.1159/000453035
  62. 62. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454. DOI: 10.1038/nature07204
  63. 63. Chen Q, Liang Y, Zhu C, Yan Y, Pang G. Effects of casein glycomacropeptide on the early development of primary colorectal cancer in rats. Food Science and Human Wellness. 2013;2:113-118. DOI: 10.1016/j.fshw.2013.09.001
  64. 64. Gong J, Chen Q, Yan Y, Pang G. Effect of casein glycomacropeptide on subunit p65 of nuclear transcription factor-B in lipopolysaccharide-stimulated human colorectal tumor HT-29 cells. Food Science and Human Wellness. 2014;3:51-55. DOI: 10.1016/j.fshw.2014.04.001
  65. 65. Takahashi N, Asakawa S, Dosako S, Tadashi I. Patent: Hypoallergenic nutritive composition. French patent. Publication date: Dec 24, 1992; publication number: 2677850
  66. 66. Mikkelsen TL, Rasmussen E, Olsen A, Barkholt V, Frøkiær H. Inmunogenicity of Κ-casein and glycomacropeptide. Journal of Dairy Science. 2006;89(3):824-830
  67. 67. Ney DM, Stroup BM, Clayton MK, Murali SG, Rice GM, Rhor F, et al. Glycomacropeptide for nutritional management of phenylketonuria: A randomized, controlled, crossover trial. American Journal of Clinical Nutrition. 2016;104:334-345. DOI: 10.3945/ajcn.116.135293
  68. 68. Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, et al. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clinical Gastroenterology and Hepatology. 2014;12(6):1012-1018. DOI: 10.1016/j.cgh.2013.08.050
  69. 69. Ney DM, Yen EC-L, Nelson DW, Solverson P. Patent: Glycomacropeptide to improve women's health. Publication date: Feb 22, 2018; publication number: US-2018/0050086 A1
  70. 70. Chung S, Moughan P, Awati A, Morton H. The influence of whey protein and glycomacropeptide on satiety in adult humans. Physiology & Behavior. 2009;96(1):162-168. DOI: 10.1016/j.physbeh.2008.09.022
  71. 71. Martin-Diana AB, Frías J, Fontecha J. Emulsifying properties of whey protein concentrate and caseinomacropeptide of cow, ewe and goat. Milchwissenschaft. 2005;60(4):363-366
  72. 72. Chobert JM, Touati A, Bertrand-Harb C, Dalgalarrondo M, Nicolas M-G. Solubility and emulsifying properties of kappa casein and its caseinomacropeptide. Journal of Food Biochemistry. 1989;13(6):457-473. DOI: 10.1111/j.1745-4514.1989.tb00413.x
  73. 73. Moreno FJ, López-Fandiño R, Olano A. Characterization and functional properties of lactosyl caseinomacropeptide conjugates. Journal of Agricultural and Food Chemistry. 2002;50(18):5179-5184. DOI: 10.1021/jf020118u
  74. 74. Wong PYY, Nakamura S, Kitts DD. Functional and biological activities of casein glycomacropeptide as influenced by lyophilization with medium and long chain fatty acid. Food Chemistry. 2006;97(2):310-317. DOI: 10.1016/j.foodchem.2005.04.019
  75. 75. Thomae-Worringer C, Siegert N, Kulozik U. Foaming properties of caseinomacropeptide– 1. Impact of concentration and interactions with whey proteins. Milchwissenschaft. 2007;62(3):249-252
  76. 76. Martínez MJ, Carrera Sánchez C, Rodríguez Patino JM, Pilosof AMR. Interactions between β-lactoglobulin and casein glycomacropeptide on foaming. Colloids and Surfaces. 2012;89:234-241. DOI: 10.1016/j.colsurfb.2011.09.022
  77. 77. Morales R, Martínez MJ, Pilosof AMR. Synergistic effect of casein glycomacropeptide on sodium caseinate foaming properties. Colloids and Surfaces B: Biointerfaces. 2017;159:501-508. DOI: org/10.1016/j.colsurfb.2017.08.017
  78. 78. Kreuß M, Krause I, Kulozik U. Influence of glycosylation on foaming properties of bovine caseinomacropeptide. International Dairy Journal. 2009;19:715-720. DOI: 10.1016/j.idairyj.2009.06.012
  79. 79. Farias ME, Martínez MJ, Pilosof AMR. Casein glycomacropeptide pH-dependent self-assembly and cold gelation. International Dairy Journal. 2010;20(2):79-88. DOI: 10.1016/j.idairyj.2009.09.002
  80. 80. Martin-Diana AB, Pelaez C, Requena T. Rheological and structural properties of fermented goat's milk supplemented with caseinomacropeptide and whey protein concentrate. Milchwissenschaft. 2004;59(7):383-386
  81. 81. Morales R, Martinez MJ, Pilosof AMR. Dynamics of gelation, textural and microstructural properties of gelatin gels in the presence of casein glycomacropeptide. Food Research International. 2016;84:102-107. DOI: 10.1016/j.foodres.2016.03.024
  82. 82. Galindo-Amaya L, Valbuena-Colmenares E, Rojas-Villarroel E. Standardization of glycomacropeptide detection with SDS–PAGE as a milk adulteration index. Revista Cientifica de Veterinaria (Maracaibo). 2006;16(3):308-314
  83. 83. Souza EMT, Arruda FS, Brandão OP, Siqueira EM. Electrophoretic analysis to detect and quantify additional whey in milk and dairy beverages. Food Science and Technology. 2000;20(3):314-317. DOI: 10.1590/S0101-20612000000300007
  84. 84. Nakano T, Ikawa N, Ozimek L. Detection of sialylated phosphorylated κ-casein glycomacropeptide electrophoresed on polyacrylamide gels and cellulose acetate strips by the thiobarbituric acid and malachite green dye reactions. Journal of Agricultural and Food Chemistry. 2007;55(7):2714-2726. DOI: 10.1021/jf062987f
  85. 85. Van Riel J, Olieman K. Determination of caseinomacropeptide with capillary zone electrophoresis and its application to the detection and estimation of rennet whey solids in milk and buttermilk powder. Electrophoresis. 1995;16(1):529-533. DOI: 10.1002/elps.1150160187
  86. 86. Lieske B, Konrad G. A new method to estimate caseinomacropeptide and glycomacropeptide from trichloroacetic acid filtrates. Milchwissenschaft. 1996;51(8):431-436
  87. 87. Van Hooydonk ACM, Olieman K. A rapid and sensitive high-performance liquid chromatography method of following the action of chymosin in milk. International Dairy Journal. 1982;36:153
  88. 88. Olieman C, van den Bedem JW. A sensitive HPLC method of detecting and estimating rennet whey total solids in skim milk powder. International Dairy Journal. 1983;37(1-2):27-36
  89. 89. Léonil J, Mollé D. A method for determination of macropeptide by cation-exchange fast protein liquid chromatography and its use for following the action of chymosin in milk. Journal of Dairy Research. 1991;58:321-328. DOI: 10.1017/S0022029900029897
  90. 90. Ferreira I, Oliveira M. Determination of caseinomacropeptide by an RP-HPLC method and monitoring of the addition of rennet whey to powdered milk. Journal of Liquid Chromatography & Related Technologies. 2003;26(1):99-107. DOI: 10.1081/JLC-120017155
  91. 91. Official Journal of the European Communities L 037. 2001. Regulation No. 213/2001, 07/02/2001. pp. 1-99
  92. 92. Pádua É, D’Amico AL, Klaechim AJ, Walter EH, Garcia B, Fagnani R. Milk adulteration with acidified rennet whey: A limitation for caseinomacropeptide detection by high-performance liquid chromatography. Journal of the Science of Food and Agriculture. 2017;98(10):3994-3996. DOI: 10.1002/jsfa.8846
  93. 93. de Carvalho BMA, de Carvalho LM, dos Reis Coimbra JS, Minim LA, de Souza Barcellos E, da Silva Junior WF, et al. Rapid detection of whey in milk powder samples by spectrophotometric and multivariate calibration. Food Chemistry. 2015;174:1-7. DOI: 10.1016/j.foodchem.2014.11.003
  94. 94. Mollé D, Léonil J. Quantitative determination of bovine k-casein macropeptide in dairy products by liquid chromatography/electrospray coupled to mass spectrometry (LC-ESI/MS) and liquid chromatography/electrospray coupled to tamdem mass spectrometry (LC-ESI/MS/MS). International Dairy Journal. 2005;15:419-428. DOI: 10.1016/j.idairyj.2004.08.013
  95. 95. Bremer M, Kemmers-Voncken Boers EAM, Frankhuizen R, Haasnoot W. Enzyme-linked immunosorbent assay for the detection of bovine rennet whey powder in milk powder and buttermilk powder. International Dairy Journal. 2008;18:294-302. DOI: 10.1016/j.idairyj.2007.08.008
  96. 96. Chávez NA, Jauregui J, Palomares LA, Macías KE, Jiménez M, Salinas E. A highly sensitive sandwich ELISA for the determination of glycomacropeptide to detect liquid whey in raw milk. Dairy Science and Technology. 2012;92(2):121-132. DOI: 10.1007/s13594-011-0052-3
  97. 97. Chávez NA, Salinas E, Jauregui J, Palomares L, Macias K. Detection of bovine milk adulterated with cheese whey by western blot immunoassay. Food and Agricultural Immunology. 2012;19:265-272. DOI: 10.1080/09540100802381042
  98. 98. Oancea S. Identification of glycomacropeptide as indicator of milk and dairy drinks adulteration with whey by immunocromatographic assay. Biotechnology Letters. 2009;14(1):4146-4151
  99. 99. Martín-Hernández C, Muñoz M, Daury C, Weymuth H, Kemmers-Voncken AEM, Corbatón V, et al. Immunochromatographic lateral-flow test strip for the rapid detection of added bovine rennet whey in milk and milk powder. International Dairy Journal. 2009;19:205-208. DOI: 10.1016/j.idairyj.2008.10.016

Written By

Juan Jauregui-Rincón, Eva Salinas-Miralles, Norma Chávez-Vela and Mariela Jiménez-Vargas

Submitted: June 19th, 2018 Reviewed: October 19th, 2018 Published: November 27th, 2018